Cargando…
Engineered nanomaterials enhance drug delivery strategies for the treatment of osteosarcoma
Osteosarcoma (OS) is the most common malignant bone tumor in adolescents, and the clinical treatment of OS mainly includes surgery, radiotherapy, and chemotherapy. However, the side effects of chemotherapy drugs are an issue that clinicians cannot ignore. Nanomedicine and drug delivery technologies...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10475588/ https://www.ncbi.nlm.nih.gov/pubmed/37670948 http://dx.doi.org/10.3389/fphar.2023.1269224 |
_version_ | 1785100751362588672 |
---|---|
author | Zhang, Haorui Luo, Ping Huang, Xiaojun |
author_facet | Zhang, Haorui Luo, Ping Huang, Xiaojun |
author_sort | Zhang, Haorui |
collection | PubMed |
description | Osteosarcoma (OS) is the most common malignant bone tumor in adolescents, and the clinical treatment of OS mainly includes surgery, radiotherapy, and chemotherapy. However, the side effects of chemotherapy drugs are an issue that clinicians cannot ignore. Nanomedicine and drug delivery technologies play an important role in modern medicine. The development of nanomedicine has ushered in a new turning point in tumor treatment. With the emergence and development of nanoparticles, nanoparticle energy surfaces can be designed with different targeting effects. Not only that, nanoparticles have unique advantages in drug delivery. Nanoparticle delivery drugs can not only reduce the toxic side effects of chemotherapy drugs, but due to the enhanced permeability retention (EPR) properties of tumor cells, nanoparticles can survive longer in the tumor microenvironment and continuously release carriers to tumor cells. Preclinical studies have confirmed that nanoparticles can effectively delay tumor growth and improve the survival rate of OS patients. In this manuscript, we present the role of nanoparticles with different functions in the treatment of OS and look forward to the future treatment of improved nanoparticles in OS. |
format | Online Article Text |
id | pubmed-10475588 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-104755882023-09-05 Engineered nanomaterials enhance drug delivery strategies for the treatment of osteosarcoma Zhang, Haorui Luo, Ping Huang, Xiaojun Front Pharmacol Pharmacology Osteosarcoma (OS) is the most common malignant bone tumor in adolescents, and the clinical treatment of OS mainly includes surgery, radiotherapy, and chemotherapy. However, the side effects of chemotherapy drugs are an issue that clinicians cannot ignore. Nanomedicine and drug delivery technologies play an important role in modern medicine. The development of nanomedicine has ushered in a new turning point in tumor treatment. With the emergence and development of nanoparticles, nanoparticle energy surfaces can be designed with different targeting effects. Not only that, nanoparticles have unique advantages in drug delivery. Nanoparticle delivery drugs can not only reduce the toxic side effects of chemotherapy drugs, but due to the enhanced permeability retention (EPR) properties of tumor cells, nanoparticles can survive longer in the tumor microenvironment and continuously release carriers to tumor cells. Preclinical studies have confirmed that nanoparticles can effectively delay tumor growth and improve the survival rate of OS patients. In this manuscript, we present the role of nanoparticles with different functions in the treatment of OS and look forward to the future treatment of improved nanoparticles in OS. Frontiers Media S.A. 2023-08-21 /pmc/articles/PMC10475588/ /pubmed/37670948 http://dx.doi.org/10.3389/fphar.2023.1269224 Text en Copyright © 2023 Zhang, Luo and Huang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Zhang, Haorui Luo, Ping Huang, Xiaojun Engineered nanomaterials enhance drug delivery strategies for the treatment of osteosarcoma |
title | Engineered nanomaterials enhance drug delivery strategies for the treatment of osteosarcoma |
title_full | Engineered nanomaterials enhance drug delivery strategies for the treatment of osteosarcoma |
title_fullStr | Engineered nanomaterials enhance drug delivery strategies for the treatment of osteosarcoma |
title_full_unstemmed | Engineered nanomaterials enhance drug delivery strategies for the treatment of osteosarcoma |
title_short | Engineered nanomaterials enhance drug delivery strategies for the treatment of osteosarcoma |
title_sort | engineered nanomaterials enhance drug delivery strategies for the treatment of osteosarcoma |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10475588/ https://www.ncbi.nlm.nih.gov/pubmed/37670948 http://dx.doi.org/10.3389/fphar.2023.1269224 |
work_keys_str_mv | AT zhanghaorui engineerednanomaterialsenhancedrugdeliverystrategiesforthetreatmentofosteosarcoma AT luoping engineerednanomaterialsenhancedrugdeliverystrategiesforthetreatmentofosteosarcoma AT huangxiaojun engineerednanomaterialsenhancedrugdeliverystrategiesforthetreatmentofosteosarcoma |